Non-small cell lung cancer (NSCLC), particularly lung adenocarcinoma, is predominantly driven by mutations in driver genes, primarily including anaplastic lymphoma kinase (ALK) rearrangements and epidermal growth factor receptor (EGFR) mutations (1). Here, ALK is linked to lung adenocarcinoma.